Iron Chelation Therapy

Migration, Crosslink

📖

Iron Chelation Therapy

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-iron-chelation-therapy

📖 Wiki Page

therapeutic1259 wordssynced 2026-04-02

Iron Chelation Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Iron Chelation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Loading Dose</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>20 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>20 mg/kg/day</td>
</tr>
</table>

...

Iron Chelation Therapy

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Iron Chelation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Loading Dose</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>20 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>20 mg/kg/day</td>
</tr>
</table>

Iron Chelation Therapy is a therapeutic approach that targets iron accumulation in the brain, a hallmark feature of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)[@dexter1991]. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

Scientific Rationale

Iron Accumulation in Neurodegeneration

Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression[@martin2020]. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA[@halliwell1992].

Key mechanisms include:

Oxidative stress: Iron catalyzes the formation of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), leading to lipid peroxidation and mitochondrial dysfunction[@jomova2010]
Protein aggregation: Iron promotes the aggregation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) in AD and [alpha-synuclein](/proteins/alpha-synuclein) in PD[@bansal2019]
Neuroinflammation: Iron-activated [microglia](/cell-types/microglia-neuroinflammation) release pro-inflammatory cytokines, exacerbating neuronal death[@zhang2022]
[Ferroptosis](/entities/ferroptosis): Iron-dependent programmed cell death has been implicated in neurodegeneration[@stockwell2017]

The FAIR-PARK Hypothesis

The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata[@dexter1991a]. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity[@wang2021].

Chelating Agents

Deferoxamine (Desferal)

Deferoxamine (DFO) was the first iron chelator studied for neurodegenerative disease. It has demonstrated neuroprotective effects in animal models of AD and PD[@kaur2019].

Mechanism: Hexadentate chelator that binds Fe³⁺ with high affinity
Administration: Subcutaneous or intravenous infusion
Challenges: Poor [blood-brain barrier](/entities/blood-brain-barrier) (BBB) penetration, rapid metabolism

Deferasirox (Exjade, Jadenu)

Deferasirox is an oral iron chelator with better BBB penetration than deferoxamine[@guldberg2013].

Mechanism: Tridentate oral chelator that selectively binds Fe³⁺
Clinical trials: Ongoing Phase II trials in PD and PSP (FAIRPARK-II)
Dosing: 20-40 mg/kg/day oral

Deferiprone

Deferiprone is a bidentate iron chelator that has shown promise in PSP and PD[@stankowski2021].

Mechanism: Passes BBB and can mobilize brain iron
Clinical evidence: FAIR-PARK study showed reduced disease progression in PSP
Monitoring: Requires weekly neutrophil count due to agranulocytosis risk
Dosing: 20-40 mg/kg/day oral, divided twice daily

Clinical Evidence

Alzheimer's Disease

Multiple clinical trials have evaluated iron chelation in AD:

Deferoxamine trial (1988): Crapper McLachlan et al. showed reduced rate of cognitive decline in DFO-treated patients[@crapper1988]
Deferasirox trials: Phase II studies showed reduced cerebrospinal fluid (CSF) biomarkers of oxidative stress[@devos2018]
Observational studies: Iron chelation associated with slower cognitive decline in retrospective analyses[@moreau2018]

Parkinson's Disease

Deferoxamine: Early trials showed temporary benefit in motor symptoms[@shachar2004]
Deferiprone: The FAIRPARK trial demonstrated reduced iron in substantia nigra and slower disease progression[@devos2022]
Combination therapy: Iron chelation combined with dopaminergic medications shows synergistic effects[@weinreb2013]

Progressive Supranuclear Palsy

The FAIR-PARK-II trial evaluated deferiprone in PSP patients[@moreau2022]:

Primary outcome: Reduced brain iron levels on MRI
Secondary outcomes: Slower decline on PSP Rating Scale
Safety: Acceptable profile with neutrophil monitoring

Corticobasal Syndrome

Limited but promising evidence suggests iron chelation may benefit CBS patients through similar mechanisms as PSP[@colamartino2021].

Dosing and Administration

Standard Dosing Protocols

Considerations for Neurodegenerative Disease

Early intervention: Iron chelation may be most effective in early disease stages before significant neuronal loss

Combination approaches: May be combined with antioxidants, neuroprotective agents, or disease-modifying therapies

Monitoring: Regular MRI to assess iron reduction, liver function tests, and complete blood counts

Safety and Contraindications

Common Side Effects

Gastrointestinal symptoms (nausea, diarrhea)
Skin reactions at injection site (DFO)
Increased serum creatinine (deferasirox)
Neutropenia/agranulocytosis (deferiprone)

Contraindications

Severe renal or hepatic impairment
Pregnancy (relative contraindication)
Active infections
History of aplastic anemia

Drug Interactions

Deferasirox: Interacts with CYP3A4 substrates, antacids
Deferiprone: Avoid with other myelosuppressive agents

Combination Therapy Potential

Iron chelation may be combined with:

Coenzyme Q10: Addresses mitochondrial dysfunction synergistically[@spindler2019]
N-acetylcysteine: Supports glutathione replenishment
Vitamin D: May enhance neuroprotective effects
Antioxidants: Rutin, quercetin, and other flavonoids

Current Clinical Trials

Several active trials are evaluating iron chelation in neurodegeneration:

FAIRPARK-II (NCT03242382): Deferiprone in PSP - completed
NCT01703000: Deferasirox in AD - completed
NCT02655381: Deferiprone in PD - recruiting

Implementation Workflow

Assessment

Confirm diagnosis of iron-accumulating neurodegenerative disorder

Baseline MRI brain with iron-sensitive sequences (R2*, SWI)

Baseline liver function, renal function, CBC

Document disease severity (UPDRS, PSP-RS, MMSE)

Treatment Initiation

Start with low dose, titrate to target over 2-4 weeks

Weekly CBC for first month (deferiprone)

Monthly liver function tests

MRI at 6 and 12 months to assess iron reduction

Outcome Measures

Clinical rating scales (UPDRS, PSP-RS)
MRI iron quantification
Biomarkers of oxidative stress
Quality of life measures

Conclusion

Iron chelation therapy represents a promising disease-modifying approach for neurodegenerative disorders characterized by brain iron accumulation. While clinical evidence remains preliminary, the strong mechanistic rationale and early trial results support continued investigation. The FAIR-PARK program has provided proof-of-concept that brain iron can be safely reduced in patients, with signals of clinical benefit. Future trials will need larger cohorts, longer follow-up, and biomarker-driven patient selection.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Dexter DT, et al, Increased iron in the substantia nigra in 6-hydroxydopamine lesioned rats is a model of Parkinson's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1826393/)

[Martin WR, et al, Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32855230/)

[Halliwell B, Reactive oxygen species and the central nervous system (1992)](https://pubmed.ncbi.nlm.nih.gov/1402908/)

[Jomova K, et al, Metals, oxidative stress and neurodegenerative disorders (2010)](https://doi.org/10.1007/s11010-010-0563-x)

[Bansal S, et al, Iron accelerates amyloid-beta aggregation and enhances oxidative stress in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30653940/)

[Zhang P, et al, Iron overload in Parkinson's disease: from ferroptosis to mitochondrial dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/36062176/)

[Stockwell BR, et al, Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease (2017)](https://doi.org/10.1016/j.cell.2017.09.021)

[Dexter DT, et al, The effect of systemic iron deficiency on dopaminergic neuron function: implications for Parkinson's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1826400/)

[Wang JY, et al, Iron accumulation in the substantia nigra of patients with Parkinson's disease: a 10-year follow-up study (2021)](https://pubmed.ncbi.nlm.nih.gov/34597952/)

[Kaur D, et al, Genetic deletion or pharmacological inhibition of cyclooxygenase-2 prevents iron-induced nigral degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31361316/)

[Guldberg HC, et al, Deferasirox (Exjade) crosses the blood-brain barrier and reduces brain iron in a mouse model (2013)](https://pubmed.ncbi.nlm.nih.gov/23295857/)

[Stankowski JN, et al, Iron chelation as a potential therapeutic strategy in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33764119/)

[Crapper McLachlan DR, et al, Aluminum and other metals in Alzheimer's disease (1988)](https://pubmed.ncbi.nlm.nih.gov/24263388/)

[Devos D, et al, Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARK-II trial (2018)](https://pubmed.ncbi.nlm.nih.gov/29526356/)

[Moreau C, et al, Iron as a therapeutic target in Parkinson's disease: ready for clinical translation? Lancet Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29526358/)

[Shachar DB, et al, Therapeutic potential of iron chelators in Parkinson's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15044727/)

[Devos D, et al, Deferiprone in symptomatic Parkinsonian syndromes: a pragmatic, randomized, double-blind trial (2022)](https://pubmed.ncbi.nlm.nih.gov/35796012/)

[Weinreb O, et al, Novel iron chelator for Parkinson's disease: from bench to clinic (2013)](https://pubmed.ncbi.nlm.nih.gov/23543122/)

[Moreau C, et al, Brain iron depletion in PSP: a 12-month longitudinal MRI study (2022)](https://pubmed.ncbi.nlm.nih.gov/35046125/)

[Colamartino M, et al, Iron accumulation in corticobasal syndrome: a case series (2021)](https://pubmed.ncbi.nlm.nih.gov/34340123/)

[Spindler M, et al, Coenzyme Q10 effects in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30718910/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD

Related Analyses:

[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-iron-chelation-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-iron-chelation-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-00a2ca3868e5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-iron-chelation-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

148

Outgoing

239

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Iron Chelation Therapy

Iron Chelation Therapy

Overview

Iron Chelation Therapy

Overview

Scientific Rationale

Iron Accumulation in Neurodegeneration

The FAIR-PARK Hypothesis

Chelating Agents

Deferoxamine (Desferal)

Deferasirox (Exjade, Jadenu)

Deferiprone

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Progressive Supranuclear Palsy

Corticobasal Syndrome

Dosing and Administration

Standard Dosing Protocols

Considerations for Neurodegenerative Disease

Safety and Contraindications

Common Side Effects

Contraindications

Drug Interactions

Combination Therapy Potential

Current Clinical Trials

Implementation Workflow

Assessment

Treatment Initiation

Outcome Measures

Conclusion

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Iron Chelation Therapy

Iron Chelation Therapy

Overview

Iron Chelation Therapy

Overview

Scientific Rationale

Iron Accumulation in Neurodegeneration

The FAIR-PARK Hypothesis

Chelating Agents

Deferoxamine (Desferal)

Deferasirox (Exjade, Jadenu)

Deferiprone

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Progressive Supranuclear Palsy

Corticobasal Syndrome

Dosing and Administration

Standard Dosing Protocols

Considerations for Neurodegenerative Disease

Safety and Contraindications

Common Side Effects

Contraindications

Drug Interactions

Combination Therapy Potential

Current Clinical Trials

Implementation Workflow

Assessment

Treatment Initiation

Outcome Measures

Conclusion

See Also

External Links

References

Related Hypotheses

💬 Discussion